ArticlePloS one2024

Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer.

Karlijn Hummelink et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.